Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis

Stroke

Volumn 41, Issue 11, 2010, Pages 2575-2580

  Coutinho, Jonathan M ^a   Ferro, José M ^b   Canhão, Patrícia ^b   Barinagarrementeria, Fernando ^c   Bousser, Marie Germaine ^d   Stam, Jan ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^d HÔPITAL LARIBOISIÈRE   (France)

Author keywords

heparin; heparin, low molecular weight; sinus thrombosis, intracranial; stroke

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; BRAIN VEIN; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL INDEPENDENCE MEASURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANKIN SCALE; SECONDARY ANALYSIS; TREATMENT OUTCOME; VEIN THROMBOSIS;

ADULT; ANTICOAGULANTS; COHORT STUDIES; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; INTRACRANIAL HEMORRHAGES; INTRACRANIAL THROMBOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 78149359985     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.588822     Document Type: Article

References (22)

1. Einhaupl K, Bousser MG, de Bruijn SF, Ferro JM, Martinelli I, Masuhr F, Stam J. EFNS guideline on the treatment of cerebral venous and sinus thrombosis. Eur J Neurol. 2006;13:553-559.
2. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352:1791-1798.
3. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol. 2007;6:162-170.
4. Stam J, de Bruijn SF, DeVeber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database Syst Rev. 2002;4:CD002005.
5. De Swart CA, Nijmeyer B, Roelofs JM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood. 1982;60: 1251-1258.
6. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119:64S-94S.
7. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
8. Lindhoff-Last E, Nakov R, Misselwitz F, Breddin HK, Bauersachs R. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Br J Haematol. 2002;118:1137-1142.
9. Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med. 2001;344:626-631
10. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;337:657-662.
11. Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992;339:441-445.
12. van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfrac-tionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2004;4:CD001100.
13. Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664-670.
14. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43-46.
15. Einhaupl KM, Villringer A, Meister W, Mehraein S, Garner C, Pellkofer M, Haberl RL, Pfister HW, Schmiedek P. Heparin treatment in sinus venous thrombosis. Lancet. 1991;338:597-600.
16. De Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke. 1999;30:484-488.
17. Coutinho JM, Stam J. How to treat cerebral venous and sinus thrombosis. J Thromb Haemost. 2010;8:877-883.
18. Fennerty AG, Thomas P, Backhouse G, Bentley P, Campbell IA, Rou-tledge PA. Audit of control of heparin treatment. BMJ (Clin Res Ed). 1985;290:27-28.
19. Hull RD, Pineo GF. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive? Semin Thromb Hemost. 2004;30(suppl 1):11-23.
20. Morabia A. Heparin doses and major bleedings. Lancet. 1986;327: 1278-1279.
21. Wheeler AP, Jaquiss RD, Newman JH. Physician practices in the treatment of pulmonary embolism and deep venous thrombosis. Arch Intern Med. 1988;148:1321-1325.
22. Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med. 1991;151:333-337.